Introduction
Despite powerful chemotherapy and/or radiotherapy regimens, patients with adult leukemia achieve long-term survival in only approximately one-third of cases. The mechanisms of obtaining drug or radiation resistance and the behavior of so-called minimal residual leukemia cells leading to relapse have been under intensive investigation. It is suggested that a novel selective therapeutic strategy, eradication of leukemia cells in a cell-specific manner without affecting normal cells, will cure these refractory hematological malignancies. [1] [2] [3] Thus, the development of immunological methods for induction of T cells specific for hematopoietic tumors or stimulation of the antileukemia functions is expected. Immunoprotection gene therapy may enhance host immunity against regrowth of leukemia cells through the administration of gene-modified autologous leukemia cells. Recent mouse studies, mainly using solid tumor models, have shown that the transduction of cDNAs encoding cytokines [4] [5] [6] [7] or costimulatory molecules [8] [9] [10] into tumor cells helped to decrease the tumorigenicity of the cells or endowed them with in vivo vaccination efficacy. Since differences in immunological properties between hematopoietic malignant cells and solid tumor cells were suggested, 11 it may be worthwhile to test the propriety of adopting immuno/gene therapeutic approaches to leukemia therapy. The fact that graftversus-leukemia (GVL) effect observed in allogeneic bone marrow transplantation (BMT) suggests that an effective immune response can cure acute leukemia. A whole-cell vaccine approach by ex vivo gene transfer in acute leukemia has many advantages. Moreover, most patients with acute leukemia achieve complete remission after conventional chemotherapy with a state of minimal residual disease that could be eradicated by the immune response induced by a gene therapy protocol. 12 Several groups have reported that the induction of an efficient and long-term autologous immunity in murine leukemia models using gene transfer IL-2, GM-CSF and costimulatory molecules. [13] [14] [15] [16] [17] [18] IL-12 gene transfer has been reported to induce the regression of a considerable preestablished leukemia burden in mice. [19] [20] [21] Recently, Reddy et al 22, 23 demonstrated that IL-18 could attenuate acute graft-versus-host disease (GVHD) without impairing the in vitro cytolytic function or the in vivo GVL activity after allogeneic BMT, suggesting that IL-18 might be a candidate for gene therapy of acute leukemia.
IL-18, a recently identified member of IL-1 family, was found to share many biological activities with IL-12 that led to a series of studies on its effects on T cells and on NK cells. 24 These studies revealed that IL-18 stimulated proliferation of Th1 and regulated survival of NK cells. IL-18 is synthesized as a biologically inactive precursor (pro-IL-18). To generate the active form of IL-18, pro-IL-18 needs to be cleaved by the intracellular cysteine protease, IL-1b converting enzyme (ICE), at the Asp-X processing site. Cleavage of pro-IL-18 by ICE facilitates secretion of the active form of IL-18. 25 As IL-18 favors the differentiation of Th1 cells that produce cytokines that are necessary for the development of cell-mediated immune responses, IL-18 has been speculated to play a prominent role in the defense against tumors. Indeed, IL-18 has been examined for its antitumoral effects in a number of murine solid tumor models of local and metastatic disease. 26, 27 Therapeutic and specific antitumor immunity was induced in vivo by directly injecting IL-18-transfected dendritic cells (DCs) or coadministration of immature DCs and adenoviral vector expressing biologically active IL-18 into tumors. [28] [29] [30] Furthermore, IL-18-transfected tumor cell vaccines and local delivery of the IL-18 gene as naked DNA by gene gun or in viral vectors have been extensively investigated. [31] [32] [33] [34] [35] [36] [37] [38] Most of these strategies have resulted in improved antitumoral effects, ranging from complete tumor regression to significantly increased survival of mice implanted with tumor cells. In contrast to numerous reports of antitumoral effects of recombinant IL-18 administration [39] [40] [41] [42] or IL-18 gene therapy with transduced tumor cells against solid tumors, there are no observations that indicate the potential efficacy of gene transfer of IL-18 in hematological malignant disease yet. Thus, in the present study, co-inoculation of pro-IL-18 and ICE modified leukemia cells was performed to assess the efficacy of antileukemic immunity in a murine model of L1210 from the more physiological viewpoint, instead of transfection of genetically engineered mature form of IL-18 cDNA.
Materials and methods

Mice and cell line
DBA/2 female mice between 6 and 8 weeks of age were purchased from Center for experimental animals, Chinese Academy of Medical Sciences and were housed in a specific pathogen-free animal facility under isothermal conditions and allowed access to food and water ad libitum. L1210, which was provided by Professor Sheng-Guo You (Laboratory of Immunology, Institute of Hematology, Peking Union Medical College), is a murine lymphoid leukemia cell line of DBA/2 origin and was maintained in Iscove's modified Dulbecco's medium (IMDM) (GIBCO) supplemented with 10% heat-inactivated fetal bovine serum and antibiotics at 371C in a humidified atmosphere of 5% CO 2 .
Reverse transcription-polymerase chain reaction RNA isolation and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) were carried out according to our previously described procedure. 43 PCR cycling parameters were denaturation for 1 min at 941C, annealing at 581C for 1 min and extension at 721C for 1 min. PCR amplification for murine pro-IL-18, ICE and GAPDH cDNA was performed for 30, 30 and 32 cycles, respectively. The primer sequences were murine pro-IL-18, (sense) 5 0 -ACCTTCCAAATCACTTCCTC-3' and (antisense) 5 0 -CAGGCGAGGTCATCACAAGG-3'; mICE, (sense) 5 0 -CTGC-GGTGTAGAAAAGAAACG-3 0 and (antisense) 5 0 -GGCACGATT-CTCAGCATAGG-3 0 ; mGAPDH, (sense) 5 0 -TTGGC CGTATT-GGTCACCTG-3 0 and (antisense) 5 0 -CAGAAGGCCATGCCAGT-GAG-3 0 . The PCR products were visualized by electrophoresis in a 1% agarose gel containing 0.5 mg/ml ethidium bromide. Densities of the amplified pro-IL-18, ICE and GAPDH were analyzed using the Kodak digital imaging system (Eastman Kodak Company, Rochester, NY, USA). Results were expressed as a ratio of quantified IL-18 or ICE product over GAPDH product.
cDNA expression plasmid construction
To construct a plasmid expressing pro-IL-18 or ICE cDNA, the full length of murine pro-IL-18 or ICE cDNA was obtained from total RNA of DBA/2 mouse spleen cells stimulated by LPS using a RT-PCR kit (Takara). The PCR product of pro-IL-18 or ICE was then individually subcloned into the expression vector pTAR-GET (Promega) via T-A cloning.
Transfection of L1210 cells
L1210 cells were transfected with 5 mg of murine pro-IL-18 or ICE expression plasmid or empty pTARGET (mock) alone using the Lipofectamine reagent (Life Technologies) according to the manufacturer's instruction. G418 (150 mg/ml) (Life Technologies), which selects for the pTARGET-neo vector, were added to the cells 48 h later. G418-resistant clones were isolated and expanded in culture medium containing 150 mg/ml of G418 for about 14 days followed by cloning by limiting dilution. The stable expression transfectants, pro-IL-18-L1210 (Lp18) and ICE-L1210 (LpICE) cells were identified by RT-PCR and flow cytometry analysis.
Bioassay for IL-18 produced from transfectants
Culture supernatants derived from the stable expression clones were harvested for use in the IL-18 bioassay. The relative bioactivity of IL-18 produced by L1210 transfectants was determined by the ability of cell supernatants to augment IFNg production in vitro according to a previously described method with some modifications. 24 In brief, mouse splenocytes (1 Â 10 6 ) were cocultured with Con A (1.25 mg/ml) in 24-well plates for 48 h. Supernatants obtained from transfected cells were added to cell suspensions of Con A-primed splenocytes (1 Â 10 6 ) in 96-well plates for 24 h. The supernatants were collected and assayed by ELISA (Diaclone) to detect IFN-g production. For each assay, a standard curve was then constructed, and each sample assayed in duplicate. The lower limit of the detection of IFN-g was o5 pg/ml.
Animal studies
Groups of DBA/2 mice were injected intraperitoneally (i.p.) with Lp18, LpICE and a mix of equal numbers of Lp18 and LpICE cells. L1210 cells transfected with pTARGET empty plasmid (LpT, mock), or wild-type L1210 cells, were injected as control. Cells were diluted in 200 ml of PBS before injection. The dose of cells is 1 Â 10 5 or 1 Â 10 6 cells per cell line per mouse. At 6 days after the inoculation, splenocytes were collected to test cytotoxic T lymphocyte (CTL) activity, NK cytotoxicity and release of cytokines. More than 50 days, survival immunized mice were rechallenged with 2 Â 10 5 parental L1210 cells, and the development of ascites and survival of mice were recorded. The ascites was collected and i.p. findings were carefully studied. The ascites volume, number of leaked RBC and number of tumor cells were further determined.
Cytotoxicity assays of CTL and NK cells
Splenic lymphocytes were isolated from the tumor-bearing mice on day 6 of inoculation. The erythrocytes were depleted with 0.83% ammonium chloride and macrophages were removed by adherence of splenocytes on plastic plates for 2 h. The nonlymphocytes were directly used as NK effector cells. The lymphocytes were cocultured with inactived L1210 (37.5 Gy) for 7 days in the presence of recombinant IL-2 (20 U/ml) and then collected as CTL effector cells. The CTL and NK cytotoxicity were determined by a CytoTox96 Assay Kit (Promega) as described in our previous work.
44 L1210 and YAC-1 cells were used as the target cells for CTL and NK cytotoxicity, respectively, and seeded into the microtiter plate at various effector to target ratios. The amount of lactate dehydrogenase (LDH) released in culture supernatants was then measured, and the percentage cytotoxicity was calculated according to the following formula: % of specific lysis ¼ 100 Â (experimental LDH releaseÀspontaneous LDH release)/ (maximum LDH releaseÀspontaneous LDH release).
IFN-g release assay
Sera were obtained from the carotid artery of mice after 10 days tumor inoculation. The fresh isolated nonadherent splenocytes at a concentration of 2 Â 10 6 cells/ml, derived from the mice after different inoculations, were stimulated with irradiated L1210 cells (37.5 Gy). Supernatants were harvested after 48 h. The levels of mouse IFN-g in sera and supernatants were assayed using ELISA kits according to the manufacturer's instructions (Diaclone).
Statistical analysis
The two-tailed Student's t-test was used for two-group comparison, and more than two means by using Kruskal-Wallis test (ANOVA). The discrete variables were compared by w 2 or Fisher's exact test. Survival curves were plotted using KaplanMeier estimates. The Mantel-Cox log-rank test was used to analyze survival data. Statistical significance was set at o0.05.
Results
Expression of pro-IL-18 and ICE in transfectants
Three independent G418-resistant pro-IL-18 clones (Lp18-1 to 3) and four independent resistant clones of ICE (LpICE-1 to 4) were isolated and expanded. After having subcultured for 10 passages, all resistant clones were then identified by RT-PCR and flow cytometry analysis. The results showed that the LpT cells had basal levels of pro-IL-18 mRNA expression. In comparison, all of the Lp18 cells (Lp18-1 to 3) expressed much higher levels of pro-IL-18 transcripts, from which the relative expression levels of pro-IL-18 varied from 1.5-to 6.5-fold increase compared to those from LpT, with most being found in Lp18-3 cells (Figure 1a) . Moreover, the stable transfected Lp18 cells were 50-70% positive for pro-IL-18 protein expression in flow cytometry analysis (data not shown). As expected, ICE mRNA was also clearly transcribed in three LpICE clones except for LpICE-2, of which LpICE-4 displayed the highest levels of ICE transcripts (Figure 1b) , whereas endogenous ICE mRNA was not detected in either LpT or in untransfected L1210 cells (data not shown). The stable clone expressing the highest levels of pro-IL-18 or ICE was then selected for further experiments. To determine if the transfection of pro-IL-18 or ICE had effects on growth of L1210 cells in vitro, a growth curve was generated by seeding cell lines at 10 5 cells/ml and counting cells in triplicate using a hemocytometer under light microscopy by trypan blue exclusion method at 24-h intervals. As shown in Figure 2 , the transfection of pro-IL-18, ICE or mock vector did not alter the growth properties of L1210 cells in vitro as assessed by doubling time or morphology.
Bioassay for IL-18 and/or ICE produced from transfectants
The coexpression of pro-IL-18 and ICE, but not pro-IL-18 alone, in COS cells results in the secretion of bioactive IL-18 protein. 45 Cleavage of pro-IL-18 by ICE results in the secretion of the active form of IL-18 from the cells. We postulated that expression of transfected ICE in tumor cells might result in cleavage of the transgenic pro-IL-18. To evaluate this hypothesis, the ability of these cells to stimulate IFN-g production in Con A-primed murine splenocytes was used as a bioassay to measure the relative levels of functional IL-18 protein (Figure 3) . The data showed that IFN-g level induced by the supernatants from combination of Lp18 and LpICE was considerably higher than that by Lp18 or LpICE alone. Specifically, IFN-g production for Lp18 plus LpICE vs Lp18 was 255747 vs 41713 pg/ml, Po0.01. Both the low level of endogenous IL-18 in untransfected cells and subsequent low level of IFN-g production, however, were significantly enhanced by the additive supernatants from LpICE or Lp18. As expected, the combinatorial delivery of Lp18 plus LpICE was superior to Lp18 or LpICE alone and resulted in the enhanced bioactivity of IL-18 in the ICE negative cell line L1210. The production of pro-IL-18 or ICE by the transfectants was stable for more than 2 months, and production fluctuated o10% in each clone. The bioactivity of culture supernatant was further identified by neutralizing IFN-g secretion with addition of antimouse IL-18 antibody (Santa Cruz) at a concentration of 5 mg/ml (data not shown).
Antitumor effects of injection of Lp18 or combination of Lp18 and LpICE
The L1210 murine lymphoid leukemic model is highly aggressive. It is well known that i.p. inoculation of mice with 1 Â 10 5 L1210 leukemia cells results in a rapid development of ascites followed by a death of all animals within 15 days. Mice injected with only 1 Â 10 2 parental L1210 all died in variably by day 32 . It has been determined that mice that survive for more than 50 days after inoculation of L1210 cells might be regarded as long-term survivors. 46 In our present study, effect of gene transfer on leukemogenicity was investigated by i.p. injection of 10 5 and 10 6 transduced or control wild L1210 cells in DBA/2 mice (n ¼ 8) (Figure 4) . In preliminary experiments, a possible effect of gene transfer of ICE alone as control on the tumorigenicity (n ¼ 5) was excluded (data not shown). We observed that mice injected with 10 5 living Lp18 and Lp18 þ LpICE cells showed significantly reduced tumorigenicity, compared to the rest two groups (Po0.01), and the combination of Lp18 þ LpICE cells was
Figure 2
In vitro growth characteristics of mock-transfected (LpT) and pro-IL-18 or ICE producing cell line (Lp18 or LpICE). Proliferation of LpT, Lp18 or LpICE cells was compared with that of parental L1210. Growth curve was generated by seeding cell lines at 10 5 cells/ml and counting cells in triplicate using a hemocytometer under light microscopy by trypan blue exclusion method at 24-h intervals. The representative data of three separate experiments are shown.
Figure 3
Induction of IFN-g secretion by culture supernatants from transfected and parent cells. Levels of IFN-g secretion from murine splenocytes were measured by ELISA. The levels of IFN-g induction by culture supernatants in the Lp18 cells (C) (10 6 cells/24 h) were between 15 and 58 pg/ml, and those levels in the LpICE cells (D) were between 45 and 77 pg/ml, whereas those levels in the pro-IL-18 or ICE transfectants (E) were between 198 and 327 pg/ml, and those levels in parent cells (A) and mock (B) showed low levels from 5 to 15 pg/ml. The fluctuations of this production at different times were o10% in each clone.
n Po0.01 vs other groups. 
Pro-IL
-18 and ICE induce antitumor effects B Zhang et al superior to Lp18 alone and differences increased when 10 6 cells were injected.
Rechallenge with parental L1210 cells and SP2/0
We next examine whether primary rejection of pro-IL-18 alone and/or pro-IL-18 þ ICE transfectants led to protective immunity (Figure 4b ). At 50 days after initial inoculation of Lp18 or Lp18 þ LpICE cells, seven surviving mice were rechallenged i.p. with 2 Â 10 5 parental L1210 cells, and all survived up to day 80, suggesting that primary injection of Lp18 or Lp18 þ LpICE cells led to protective immunity. Moreover, no abnormal pathologic findings in these mice with long-term survival were observed. Seven nonimmunized mice were injected in the same manner as control, which grew progressively until the animal died. To demonstrate the specificity of the protective immunity, SP2/0 cells were injected into nonimmunized and immunized mice (n ¼ 7). There was no significant difference in the growth of implanted SP2/0 cells between both groups (data not shown).
Combinatorial injection of Lp18 and LpICE inhibits the accumulation of bloody ascites
Production and characteristics of ascites are important for assessment on the aggressiveness of L1210 leukemia. We found that the injection of Lp18 or combination of Lp18 þ LpICE apparently delayed the production of ascites approximately 3-4 days, though could not completely inhibit the formation of ascites, whereas in rest both groups each developed the ascites in 10 days after inoculation (Table 1) . Even more importantly, the accumulation of bloody ascites was observed at day 10 following the injection of tumor cells in all treated groups except for in the combinatorial inoculation of Lp18 and LpICE, which is strengthened by the fact that there was remarkable dissemination of blood cells and infiltration of L1210 leukemia cells by Wright-Giemsa staining on the smear of ascites fluid from the rest four groups (data not shown). To better understand the effects, we then quantified the characteristics of ascites including ascites volume, number of tumor cells and number of RBC in ascites fluid. As shown in Table 1 
Augmented NK activities induced by the delivery of Lp18/Lp18 plus LpICE
Splenocytes derived from the leukemia-bearing mice that had been killed after various therapies were used in cytolytic assays against YAC-1 cells at effector:target (E:T) ratio of 1:1, 5:1, 10:1 and 20:1 by a standard LDH released assay. As shown in Figure 5a , the NK activity of lymphocytes from the mice with inoculation of wild-type L1210, LpT or LpICE was low with approximately 10-30% cytotoxic activity at various E/T ratio, but increased significantly with about 35-60% cytotoxic activity after the mice were injected with Lp18 or Lp18 þ LpICE. The NK activity of the mice injected with Lp18 þ LpICE was higher than that of the mice injected with Lp18 or LpICE alone (Po0.05). There was no significant difference in NK activity between the other three groups. The data suggested that the augmented nonspecific immunity might be involved in the antitumor responses of the combined therapy of Lp18 and LpICE vaccine.
Induction of CTL activity after cellular vaccine of Lp18/Lp18 plus LpICE
Lymphocytes isolated from leukemia-bearing mice of different groups that had been killed were cocultured with inactivated L1210 cells (37.5 Gy) for 7 days in the presence of recombinant murine IL-2 (20 U/ml), then collected as CTL effector cells and L1210 cells were used as target cells. The CTL activity was determined at E:T ratios of 1:1, 5:1, 10:1 and 20:1 by a standard Table 1 Effects on the accumulation of ascites derived from ascites-bearing mice after tumor inoculation Pro-IL-18 and ICE induce antitumor effects B Zhang et al LDH released assay. As shown in Figure 5b , splenic CTL activity of Lp18 or Lp18 þ LpICE-treated mice with approximately 20-50% cytotoxic activity was higher than that of LpICE, LpT or wild-type L1210-inoculated group with only about 10-30% cytotoxic activity (Po0.05). The highest CTL activity was induced in mice inoculated with Lp18 þ LpICE compared to that in mice of other groups (Po0.01). It suggested that tumorspecific immunity was induced most significantly by the combine therapy of Lp18 þ LpICE vaccine, especially when Th1 response was enhanced, which possibly supported the further development of specific protective immunity against parental L1210.
Production of IFN-g was not altered significantly in vivo by gene transfer of pro-IL-18/ICE cDNA To examine whether IFN-g is the main mediator of IL-18 antileukemic activity or not, the levels of IFN-g in the culture supernatants of spleen cells treated with irradiated L1210 or in the sera derived from the mice 10 days after vaccine inoculation were measured. In contrast with the above, we observed no significant elevation in circulating IFN-g in the mice injected with Lp18 or combination of Lp18 and LpICE, compared to that in the mice injected with LpICE, LpT or wild-type L1210 cells. Similarly, the culture supernatants of irradiated L1210-stimulated spleen cells derived from the mice injected with Lp18 or combination of Lp18 þ LpICE only contain slightly larger amounts of IFN-g than the LpICE, LpT or wild-type L1210-inoculated mice ( Figure 6 ). Furthermore, there was also no significant difference in the levels of IFN-g in sera between 2, 5 or 8 days after tumor inoculation (data not shown). The results suggested Lp18 or Lp18 plus LpICE vaccine failed apparently to induce high levels of IFN-g though augmented splenic NK cell activity.
Discussion
Cytokine immunotherapy is being increasingly used as an adjunct to conventional chemotherapy/radiotherapy to treat hematological malignant disease. However, systemic therapy with cytokines is associated with severe toxic side effects. In order to optimize the antitumoral effect and to minimize the toxic side effects of cytokines, various gene therapy approaches, including the use of transduced tumor cell vaccines and local delivery of cytokine genes as naked DNA to tumors growing, have been adopted. As IL-18 gene therapy has shown promising antitumoral activity in various solid tumor models, [31] [32] [33] [34] [35] [36] [37] [38] we sought to develop an IL-18-based consolidating adjuvant therapy for leukemia using L1210 cell vaccines to deliver IL-18 in vivo. So far as we know, this is the first evidence that a Figure 5 Injection of Lp18 alone or combinatorial Lp18 plus LpICE enhances both NK and CTL activities. (a) Splenic lymphocytes isolated from tumor-bearing mice of different groups 6 days after inoculation were used in NK cytolytic assays against YAC-1 cells at effector:target (E:T) ratios of 1:1, 5:1, 10:1, 20:1 by a standard LDH release assay. (b) Lymphocytes isolated from tumor-bearing mice after various therapies were cocultured with inactivated L1210 (37.5 Gy) for 7 days in the presence of recombinant murine IL-2 (20 U/ml) and then collected as CTL effector cells. The L1210 cells were used as target cells. The tumor-specific CTL cytotoxicity was determined at E:T ratios of 1:1, 5:1, 10:1, 20:1 by a standard LDH release assay.
Figure 6
Production of IFN-g in serum (a) or in culture supernatants of lymphocytes (b) derived from leukemia-bearing mice and stimulating with irradiated L1210 cells in vitro. No significantly enhanced IFN-g production was observed in Lp18 or Lp18 þ LpICE group. IFN-g levels were determined by ELISA kits.
combinatorial direct treatment with pro-IL-18 and ICE cDNA can result in pronounced prolongation of survival time in an established murine leukemia model. A previous report also demonstrated the efficacy of the combination of pro-IL-18 and ICE by gene gun in a murine solid tumor model, which strongly supported our data here. 32 Recent studies have revealed that greater therapeutic efficacy using vaccines consisting of tumor cells transduced with multiple genes compared with single-gene vaccines. 47 IL-18, which is related structurally to IL-1b, is originally synthesized as a leaderless precursor, and it needs ICE for cleavage into a mature activator. Increased amount of bioactive IL-18 secretion appears to be necessary to achieve better antitumor effects. It has been reported that the dose of IL-18 administered correlates well with the resultant level of serum IFN-g and the strength of its antitumor activity. 48 Indeed, the extensive analysis of Lp18 or LpICE has revealed stable transgenic expression, as evidenced by the continuous secretion of significant amounts of IL-18 protein by transduced cells over 42 months (data not shown). The supernatants from combination of Lp18 and LpICE induced a over six-fold increase of IFN-g production in the Con A-primed murine splenocytes, compared to that from Lp18 alone in vitro, suggesting that combinatorial delivery of Lp18 and LpICE together may lead to secretion of more bioactive IL-18 protein than Lp18 or LpICE alone. Moreover, the following efficacy in vivo by combinatory gene therapy of Lp18 and LpICE vaccine was obviously superior to that by Lp18 or LpICE alone in our present study, while pro-IL-18 transfection into Lewis lung carcinoma cells only reduced tumorigenicity to some degree in vivo. 49 Antitumor effects of IL-18 administered systemically in a murine T-cell leukemia/ lymphoma EL-4 model have also been reported. 50 Their result suggested that IL-18 was only highly effective in a less aggressive tumor model of tumor burden on inhibiting the development of EL-4 lymphoma dissemination. In contrast, relatively higher efficacy was observed in treated mice in our experiments using the combinatorial gene therapy protocol with the nonvirus vectors, which was even able to inhibit the development of bloody ascites entirely and develop the specific immunity against parental cells. A plasmid vector is easy and relatively safe to handle, and it is not necessary to set up an antiviral unit or fear toxic viral infection. The administration of IL-18-secreting L1210 cells (1 Â 10 6 cells) was well tolerated, because it produced no measurable toxicity (i.e. body weight loss, lethargy, intestinal bleeding, etc), which has been partly reported in animals after systemic IL-18 therapy. 48 Therefore, our data suggest that nonvirus vector-mediated delivery of pro-IL-18/ICE genes may be clinically desirable and safe as a strategy for gene therapy in acute leukemia.
Among the several immunomodulatory activities of IL-18, its ability to induce the production of IFN-g and activation of Th1 and NK cells in vivo is the most prominent. 24, 25 We next investigated whether injection of Lp18 or Lp18 plus LpICE into mice would also induce these immune responses. NK cell cytotoxicity and CTL activity against YAC-1 and L1210 cells in various treated group were hence analyzed. It is known that tumor rejection-induced local secretion of cytokines is mediated by a dual mechanism involving specific and nonspecific antitumor effects. IL-18 plays key roles in the regulation of cellular immunity. IL-18 has been shown to be quite effective in inducing antitumor immune responses and increasing CTL and/ or NK activities in a variety of solid tumor models. [31] [32] [33] [34] [35] [36] [37] [38] In agreement with this, in our present study, combination of Lp18 and LpICE cells vaccine markedly elevated CTL and NK activities in vivo, which may lead to a stronger antileukemic effect than Lp18 or LpICE alone. The data here showed that IL-18 þ ICE gene therapy with tumor cell vaccines may prove beneficial, at least against leukemia that are sensitive to CTL and NK cells. With regard to the specific effects, our results also indicated that in vivo IL-18 probably stimulated the sensitization of memory T cells, which contributed to specific long-lasting antitumor protection. Immunized DBA/2 mice after the primary inoculation, which rejected Lp18 and Lp18 þ LpICE, were protected against parental L1210 leukemia, but not against SP2/0 tumors.
Recently, the enhancement of antitumor activity mediated by IFN-g by the treatment with IL-18 alone 39, 50 or combination of IL-18 and IL-12 in various solid tumor models was described. 40, 41 On the other hand, other groups have reported very inconsistent data about effect of inducible IFN-g on the immune response in animal models. For instance, Osaki et al 48 reported that following administration of IL-18 expression of IFN-g in tumor was not altered, and the antitumor effects of IL-18, represented by delayed emergence and growth retardation, were abrogated only marginally in IFN-g gene knockout mice, suggesting IL-18 administration mediates antitumor immune reaction independent of IFN-g pathway, unlike IL-12. Meanwhile, they also pointed out that the excess levels of IFN-g induced by injection of both IL-18 and IL-12 produced several side effects, and were the main cause of hepatotoxicity, although IFN-g is an essential cytokine for NK cell activation. Arai et al 51 indicated IL-18 alone or combined with IL-2 was effective at augmenting splenic NK activity without inducing high levels of IFN-g, regardless of the experimental mouse strain. Similarly, our present data suggested that either injection of Lp18 or Lp18 plus LpICE failed apparently to induce high levels of IFN-g in sera and the culture supernatants of spleen cells treated. Therefore, the antitumor effects mediated by IFN-g seem to depend on the types of tumors. In addition, Akamatsu et al 50 reported that IL-18 had no direct antiproliferative activity against EL-4 cells, and IFN-g had minimal inhibitory effect on EL-4 cell growth. In our previous study, 43, 52 we demonstrated that IL-18 as well as IFN-g had no apparent direct effects on leukemic cells, despite the co-expression of IL-18 and it receptor on the same cells. Therefore it is certain that IL-18 did not directly kill the leukemic cells at least via IFN-g, though we have not yet elucidated the exact mechanism underlying for antileukemic activity of IL-18.
The activation of both NK and CTL activity after injection of Lp18 cells or Lp18 þ LpICE cells provides an indication of the mechanism of the antileukemic effect of IL-18 gene therapy in the present studies. The inhibition of tumor angiogenesis and other immune cellular events have also been shown to be important in the IL-18-mediated rejection of tumors. 53, 54 Both CD8 þ and CD4 þ T-cell subsets have been shown to infiltrate tumors with local IL-18 therapy; 37 however, CD8 þ T cells were found to be critical in the destruction of tumors. 32, 37, 39 In addition, activated macrophages have also been implicated in tumor regression after IL-18 therapy. 34 Whether these immune effector mechanisms are also activated and participate in the antileukemic activity IL-18 gene therapy with tumor cell vaccines as shown in this study remains to be investigated. To increase the efficacy of tumor cell-based IL-18 gene therapy of leukemia, we are currently testing several variations in the treatment protocol (e.g. combined with the costimulatory molecules or immunomodulators), including the administration of transduced cells after debulking of leukemia burden with cytotoxic chemotherapy.
In summary, we used a syngeneic murine L1210 lymphoid leukemia model to evaluate the capacity of gene transfer of pro-IL-18/ICE cDNA to reduce the leukemogenicity and develop the specific protective immunity. Activated NK cell activity and induction of tumor-specific CTL response without high levels of IFN-g contributed to the enhanced antitumor efficacy of combined pro-IL-18/ICE genes therapy, which inhibited the accumulation of bloody ascites and allowed some mice to survive long-term. Our results demonstrate that IL-18 is a candidate gene for use in gene therapy of lymphoma or lymphoid leukemia, and that ex vivo combinatorial delivery of pro-IL-18/ICE cDNAs either as a single approach or as an adjunct to radiotherapy or chemotherapy may be more efficient in a situation of minimal residual disease. The rigorous evaluation of data obtained in various animal models is essential for further starting gene therapy clinical trials in acute leukemia.
